Yahoo Web Search

Search results

1. • ASCO: New ‘Armored’ CAR produces significant r | Newswise

     Newswise· 5 days ago

     CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients ...

2. • Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of...

     Morningstar· 1 day ago

     Gilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC-9 mCRC Study, Etrumadenant ...

3. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

     Roanoke-Chowan News-Herald· 4 days ago

     Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment ...

4. • For Your Health for June 3, 2024

     The Martinsburg Journal· 18 hours ago

     First United Bank & Trust with the American Red Cross will hold a blood drive from noon to 6 p.m. on Wednesday, June 5. The drive will be held at The Church at Martinsburg at 50 Monroe Street ...

5. • BioInvent to Host Virtual KOL Event to Highlight Recently Presented Efficacy Data from BioInvent's...

     Digital Journal· 4 days ago

     LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,

6. • Small Business - The Brewton Standard | The Brewton Standard

     The Brewton Standard· 2 days ago

     Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate ...

7. • Clinical trials show promise in treating central n | Newswise

     Newswise· 3 days ago

     Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lym

8. • Small Business - Salisbury Post | Salisbury Post

     The Salisbury Post· 22 hours ago

     -- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles

9. • 

     Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...

     Investing.com· 4 days ago

     In their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...

10. • 

      The Health Scare That Pushed Jonathan Yeo to Paint, and Why King Charles Had Him Seeing Red

      The Wall Street Journal· 6 days ago

      The royal portraitist wasn’t sure he’d end up a painter, but a cancer diagnosis changed everything....